Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

A new blood test test could determine how far Alzheimer's has progressed and could also help confirm whether another ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

A new blood test identifies a key biomarker for Alzheimer’s disease, which may help make assessing the presence and stage of ...

Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer's ...

Alzheimer’s disease is notorious for robbing individuals of memory and cognitive function. Researchers have struggled for ...

Biomarker testing also extends beyond cancer care. The science is being used in the treatment of other diseases including ...

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

It wasn't that long ago that the only way to test for Alzheimer's disease was to perform an autopsy on someone who had been ...

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain inflammation.